Skip to content

Public FDA record

Z-1799-2020: SYNCHRON Systems Barbiturates Reagent (BARB 1 X 250); Catalog No. 475012 - Product Usage: BARB reagent, i

Recall record Z-1799-2020 for Beckman Coulter Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-1799-2020
Company in FDA record
Beckman Coulter Inc.
FDA record creation date
Apr 24, 2020
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

The firm has identified that cross-reactivity testing may not meet the claims indicated in the Barbiturates Reagent Chemistry Information Sheet (CIS). The presence of certain compounds in urine may result in false positive or false negative results.

Source facts

Action
On 06/12/2019, an Urgent Medical Device Recall Letter was sent to customers via first class mail and/or email informing them that the firm has identified, through study results, that cross-reactivity testing may not meet the claims indicated in the Barbiturates Chemistry Information Sheet (CIS). Customers were informed that the presence of the following compounds in urine may lead to false negative results: Barbital at a concentration of 1500 to ~1700 ng/mL; Butabarbital at a concentration of 250 to ~300 ng/mL; Butalbital at a concentration of 400 to ~500 ng/mL; Diallybarbital at a concentration of 600 to ~700 ng/mL; Pentobarbital at a concentration of 500 to ~600 ng/mL; Phenobarbital at a concentration of 800 to ~900 ng/mL; Talbutal at a concentration of 80 to ~125 ng/mL. Customers were also informed that the presence of Glutethimide in urine at a concentration of ~ 8 to 80 g/mL may lead to false positive results. Customers were instructed to discontinue use and discard all BARB reagent lots M903174 and older following their laboratory's disposal protocol. Customers were informed that negative results due to the differences between the claimed and actual cross reactivity concentrations are not clinically significant, and that per the current Chemistry Information Sheet for this product, the reporting of a positive result by this assay should be confirmed by another generally accepted nonimmunological method; therefore retrospective review of patient results is not required. Customers were requested to share this information with their laboratory staff and retain this recall notification as part of their laboratory Quality System documentation. If customers forwarded any of the affected product listed to another laboratory, they were requested to provide that laboratory a copy of Urgent Recall Notification Letter. Customers were requested to respond to Beckman Coulter within 10 days, electronically if the customer received the notification by email; or manu
Initiated
2019-06-12
Root cause
Under Investigation by firm
Terminated
2020-12-11
Distribution
Worldwide distribution - US Nationwide distribution and to multiple countries.
Recall number
Z-1799-2020
Recall status
Terminated
CDRH record ID
180161
FDA record created
2020-04-24
Recall event number
85140

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗